Verastem Inc (NASDAQ:VSTM) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,872,660 shares, an increase of 58.3% from the December 31st total of 1,182,985 shares, AnalystRatingsNetwork.com reports. Currently, 6.2% of the company’s shares are short sold. Based on an average daily trading volume, of 373,113 shares, the short-interest ratio is currently 5.0 days.

Verastem (NASDAQ:VSTM) opened at 1.20 on Friday. The firm’s market cap is $44.32 million. The stock’s 50 day moving average is $1.61 and its 200 day moving average is $3.73. Verastem has a one year low of $1.18 and a one year high of $12.35.

Several equities analysts recently issued reports on VSTM shares. Cantor Fitzgerald upgraded shares of Verastem from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Wednesday, January 13th. Oppenheimer restated a “market perform” rating on shares of Verastem in a report on Wednesday, November 11th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $3.00.

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The Company’s programs target the Focal Adhesion Kinase (NASDAQ:VSTM) and the PI3K/mTOR signaling pathways. The Company has technology to create a stable population of cancer stem cells that it uses to screen for and identify small molecule compounds that target cancer stem cells. The Company’s solution includes the discovery and development of oncology therapeutics targeting cancer stem cells (CSCs). The Company is engaged in running clinical trials in cancers where CSCs were implicated in disease progression, including mesothelioma, ovarian, non-small cell lung and other cancers, such as breast cancer. The Company’s candidates include its FAK inhibitors, VS-6063 and VS-4718, and VS-5584, its dual mTORC1/2 and PI3K inhibitor.

12 Month Chart for NASDAQ:VSTM

Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.